ET Shows Favorable Physical Health Decline Data vs Chemo in Breast Cancer

News
Video

Endocrine therapy as a treatment for breast cancer showed similar long-lasting physical health decline data as what was seen in women who did not have breast cancer.

A recent study published in JAMA Network Open found that, in patients with breast cancer, those who received treatment with chemotherapy experienced a long-lasting decline in physical health when compared with those who were treated with endocrine therapies. CancerNetwork® interviewed Clara Bodelon, PhD, MS, senior principal scientist of survivor research at the American Cancer Society and lead study author, about the results they uncovered.

Bodelon stated that, though it’s been known that cancer treatments cause physical health declines, they set out to complete this study in hopes of finding out if certain specific types of therapy have more severe or diminished effects.

They found that within 2 years, between 2 and 5 years, and from 5 years on, patients who received chemotherapy had more substantive declines from baseline compared with those who received endocrine therapy or those who were cancer-free.

Transcript:

There have been well-designed studies that have looked at the long-term effects of physical health decline among cancer survivors in general, and breast cancer survivors. One of the things that we have seen is that all cancer survivors, and in particular breast cancer survivors, have a [physical health] decline compared with similar women of the same age. It’s thought that it’s due to the cancer and the cancer treatments, but it has been a general view [held about] the cancer survivors, and we wanted to specifically look at the different treatments that women with breast cancer will receive and see whether we saw the same effects dependent on the treatment that they received.

[In] women who received chemotherapy, what we saw is that they have long-term effects within the first 2 years after a cancer diagnosis, 2 to 5 years [after the diagnosis], and more than 5 years after the cancer diagnosis, and we saw that, compared to cancer-free women of the same age, they have declines in their physical health. However, in the women who received endocrine therapy, we saw that, after the first 2 years, the physical health was similar to that of cancer-free [women] of the same age, suggesting that those who receive endocrine therapy do not have long-lasting effects. At least with the physical health aspects like physical functioning, they may be similar to those who never had cancer to start with.

Reference

Bodelon C, Masters M, Bloodworth DE, et al. Physical health decline after chemotherapy or endocrine therapy in breast cancer survivors. JAMA Netw Open. 2025;8(2):e2462365. doi:10.1001/jamanetworkopen.2024.62365

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Future findings from a translational analysis of the OVATION-2 trial may corroborate prior clinical data with IMNN-001 in advanced ovarian cancer.
The dual high-affinity binding observed with ISB 2001 may avoid resistance mechanisms reported with other BCMA-targeted therapies.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Ankit Bharat, MBBS, a thoracic surgeon, discussed potential treatment emergent adverse effects or complications, as well as strategies for managing them.
Related Content